XO Life raises €4M to accelerate European expansion of its AI-powered brite™ platform

XO Life, the fastest-growing patient-pharma platform in Europe, has successfully closed a €4 million funding round to accelerate its European expansion and scale its AI-driven brite™ platform. The round was led by Fil Rouge Capital, one of the leading venture capital firms in the Southeast European region, with continued participation from existing investors Sandwater, Grazia Equity, Vi Partners, and Bayern Kapital, alongside other current shareholders.

The investment will be used to accelerate XO Life's growth trajectory toward Series A, meet increasing market demand, and drive its internationalization strategy across Europe, the Middle East, and Africa. XO Life's proprietary brite™ platform connects patients, healthcare professionals, and pharmaceutical companies across the entire therapy journey, providing verified medical content, personalised insights, and continuous digital therapy support across more than 40 indications and in partnership with over 40 pharmaceutical companies, including three of the ten largest global players.

Dr. Friderike Bruchmann, CEO and Co-Founder of XO Life, stated that the funding reflects the strong demand for a unified, high-quality patient-pharma platform and will allow the company to accelerate the development of brite™, leverage AI across all features, and automate pharma onboarding across entire portfolios.

For more information, visit https://www.xo-life.com/en/news